WO2020086747A2
|
|
Ssao inhibitors and uses thereof
|
WO2020061117A1
|
|
Farnesoid x receptor agonists and uses thereof
|
WO2020061118A1
|
|
Farnesoid x receptor agonists and uses thereof
|
CA3112414A1
|
|
Farnesoid x receptor agonists for the treatment of disease
|
WO2020061115A1
|
|
Crystalline forms of a farnesoid x receptor agonist
|
WO2020061116A1
|
|
Farnesoid x receptor agonists and uses thereof
|
CA3112411A1
|
|
Farnesoid x receptor agonists and uses thereof
|
WO2020061112A1
|
|
Farnesoid x receptor agonists and uses thereof
|
WO2019241751A1
|
|
Ssao inhibitors and uses thereof
|
US2020131142A1
|
|
Farnesoid x receptor agonists and uses thereof
|
EP3596053A1
|
|
Farnesoid x receptor agonists and uses thereof
|
WO2018170173A1
|
|
Farnesoid x receptor agonists and uses thereof
|
US2020131132A1
|
|
Farnesoid x receptor agonists and uses thereof
|
CA3056019A1
|
|
Farnesoid x receptor agonists and uses thereof
|
WO2018018010A1
|
|
Fgf mutants and uses thereof
|
WO2017049177A1
|
|
Farnesoid x receptor agonists and uses thereof
|
WO2017049173A1
|
|
Farnesoid x receptor agonists and uses thereof
|
EP3350164A1
|
|
Farnesoid x receptor agonists and uses thereof
|
US2018244606A1
|
|
Farnesoid X receptor agonists and uses thereof
|